BACKGROUND: We conducted a case-control study to identify risk factors for efflux overexpression, an important mechanism of fluoroquinolone resistance, among patients with fluoroquinolone-resistant Escherichia coli (FQREC) gastrointestinal tract colonization. METHODS: Three annual fecal surveillance surveys were performed hospital-wide, and all patients colonized with FQREC (levofloxacin minimum inhibitory concentration, ≥8 μg/mL) were included in the study. Cases and controls were defined on the basis of overexpression of the AcrAB efflux pump, as measured by the organic solvent tolerance (OST) assay. A multivariable logistic regression model was developed to identify risk factors for OST positivity among patients with FQREC colonization. RESULTS: Eighty-nine patients were colonized with FQREC: 44 (49.4%) and 45 (50.6%) patients had isolates that were OST-positive and OST-negative, respectively. On multivariable analyses, location on the surgical service was significantly associated with recovery of an OST-positive isolate (odds ratio, 7.36; 95% confidence interval, 1.82-29.7; P = .005). Furthermore, patients who had received a first-generation cephalosporin in the 30 days prior to sampling were less likely to have an OST-positive isolate (odds ratio, 0.20; 95% confidence interval, .04-.94; P = .04). CONCLUSIONS: Among phenotypically identical FQREC isolates, different factors may drive the emergence of different resistance mechanisms. Further studies are needed to elucidate the relationship between antimicrobial use and specific resistance mechanisms.
BACKGROUND: We conducted a case-control study to identify risk factors for efflux overexpression, an important mechanism of fluoroquinolone resistance, among patients with fluoroquinolone-resistant Escherichia coli (FQREC) gastrointestinal tract colonization. METHODS: Three annual fecal surveillance surveys were performed hospital-wide, and all patients colonized with FQREC (levofloxacin minimum inhibitory concentration, ≥8 μg/mL) were included in the study. Cases and controls were defined on the basis of overexpression of the AcrAB efflux pump, as measured by the organic solvent tolerance (OST) assay. A multivariable logistic regression model was developed to identify risk factors for OST positivity among patients with FQREC colonization. RESULTS: Eighty-nine patients were colonized with FQREC: 44 (49.4%) and 45 (50.6%) patients had isolates that were OST-positive and OST-negative, respectively. On multivariable analyses, location on the surgical service was significantly associated with recovery of an OST-positive isolate (odds ratio, 7.36; 95% confidence interval, 1.82-29.7; P = .005). Furthermore, patients who had received a first-generation cephalosporin in the 30 days prior to sampling were less likely to have an OST-positive isolate (odds ratio, 0.20; 95% confidence interval, .04-.94; P = .04). CONCLUSIONS: Among phenotypically identical FQREC isolates, different factors may drive the emergence of different resistance mechanisms. Further studies are needed to elucidate the relationship between antimicrobial use and specific resistance mechanisms.
Authors: Melinda M Neuhauser; Robert A Weinstein; Robert Rydman; Larry H Danziger; George Karam; John P Quinn Journal: JAMA Date: 2003-02-19 Impact factor: 56.272
Authors: Ebbing Lautenbach; Brian L Strom; Irving Nachamkin; Warren B Bilker; Ann Marie Marr; Lori A Larosa; Neil O Fishman Journal: Clin Infect Dis Date: 2004-02-17 Impact factor: 9.079
Authors: Jennifer H Han; Warren B Bilker; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Neil O Fishman; Ebbing Lautenbach Journal: Infect Control Hosp Epidemiol Date: 2013-08-23 Impact factor: 3.254
Authors: Jennifer H Han; Charles Garrigan; Brian Johnston; Irving Nachamkin; Connie Clabots; Warren B Bilker; Evelyn Santana; Pam Tolomeo; Joel Maslow; Janice Myers; Lesley Carson; Ebbing Lautenbach; James R Johnson Journal: Diagn Microbiol Infect Dis Date: 2016-11-28 Impact factor: 2.803
Authors: Jennifer H Han; Brian Johnston; Irving Nachamkin; Pam Tolomeo; Warren B Bilker; Xiangqun Mao; Connie Clabots; Ebbing Lautenbach; James R Johnson Journal: Antimicrob Agents Chemother Date: 2014-09-08 Impact factor: 5.191